Publications by authors named "Jie-Xuan Hu"
Ocul Immunol Inflamm
August 2022
Article Synopsis
- A meta-analysis was conducted to evaluate the risks of ocular adverse events caused by immune checkpoint inhibitors (ICIs) compared to chemotherapy, as there is limited research on this topic.
- The analysis found that PD-1/PD-L1 inhibitors had a significantly lower rate of treatment-related and nonspecific ophthalmic adverse events than chemotherapy, indicating a safer profile.
- However, when using combination therapy (PD-1 with CTLA-4), the risk of both ophthalmic treatment-related adverse events and immune-related adverse events increased compared to monotherapy.
